ReviewCureus2025
Effect of Empagliflozin on Cardiovascular Mortality and Heart Failure Hospitalizations: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has demonstrated clinically meaningful benefits in patients with heart failure (HF). This systematic review and meta-analysis aimed to assess the effect of empagliflozin on cardiovascular mortality and hospitalization for heart failure (HHF) across randomized controlled trials (RCTs). A comprehensive literature search was conducted across PubMed, Embase, Scopus, and Google Scholar, identifying five eligible RCTs. Studies were included if they evaluated empagliflozin's impact on cardiovascular mortality and HHF. A meta-analysis was performed using hazard ratios (HRs) for cardiovascular death and HHF. Data were synthesized using fixed- or random-effects models based on the degree of heterogeneity. The meta-analysis included 23,344 patients, of whom 12,849 received empagliflozin. Cardiovascular mortality was significantly reduced with empagliflozin (HR 0.86; 95% CI: 0.78-0.96). For HHF, empagliflozin reduced the risk by 30% (HR 0.70; 95% CI: 0.64-0.77) across all trials. Sensitivity analysis confirmed the robustness of these results. Empagliflozin significantly reduces cardiovascular mortality and HHF, supporting its use as a cornerstone therapy in heart failure management, especially in patients at high cardiovascular risk. These findings highlight the potential of empagliflozin as a key therapeutic intervention in heart failure care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.